Nasta, Nafiza .

HRN: 15-10-33  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/30/2025
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/30/2025
10/06/2025
IV
500MG
Q8H
AMEBIASIS
Waiting Final Action 
09/30/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
09/30/2025
10/07/2025
IV
600mg
Q8
Infected Wound Breast, Right
Waiting Final Action 
10/05/2025
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
10/05/2025
10/12/2025
IV
1.5 G
Q8
Mastitis
Waiting Final Action 
10/08/2025
CEFTRIAXONE 1G (VIAL)
10/08/2025
10/14/2025
IV
2g
OD
Mastitis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: